tbuckley/cabot-search huggingface dataset:
AB1226-HPR Vaccination compliance in autoimmune inflammatory rheumatic diseases (AIRDS): role of specialist nurse
Authors: RD Thakran, SS Baghel, R Rawat, C Messi, S Kapoor, S Garg, AN Malaviya
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The patients with autoimmune inflammatory rheumatic diseases (AIRDs) have double the risk of infections as compared to the general population this may be due to highly inflammatory nature of the disease, the drug used, and the co-morbidities. In recent years, the efficacy of vaccinations has been proven in decreasing morbidities and mortality among these patients, hence, it reduces the cost of the treatment and improves the quality of life of the patients. However, low vaccination compliance is a global problem. Therefore, in this study, we tried to assess the effect of nursing counselling on vaccinations compliance. <h3>Objectives</h3> To assess the efficacy of counseling by the specialist rheumatology nurses in vaccination compliance among AIRDs patients. <h3>Methods</h3> - All the adult patients (&gt;18yrs), suffering from AIRDs, were advised vaccinations between January to December 2016 were enrolled in this study. The basic demographic and disease-related data captured with details of vaccinations such as date of advice of vaccination and reasons for non-compliance were recorded. The patients were intensely counselled by specialist nurses about the importance and needs of vaccination, clarifying their doubts. Reinforcement of the same was carried out in the follow-up visits. <h3>Results</h3> A total of 506 patients (374 female, 73.9.2% and 132 male, 26%), with mean age 48 years, diagnoses; rheumatoid arthritis: 378 (74.75%), Spondyloarthropathy: 80 (15.81%) other autoimmune rheumatic disease 48 (9.48%). Co-morbidities status: 309 (61%) having multiple co-morbidities and 197 (38.9%) have no co-morbidities. The vaccination compliance outcome is shown in table. <h3>Conclusions</h3> The compliance rate of all vaccinations was highest on the same day when it was prescribed. This was despite the fact that the patients pay for their own vaccinations without any third party payment. However, the compliance decreases with increase in the period when it was prescribed with the passage of time. This suggests that intense counselling, availability of vaccines at premises (pharmacy) and administration of vaccination free of cost are a few of the contributory factors which can boost the compliance of the vaccination among patients with AIRDs <h3>References</h3> S.Shaffu, S.Mumtaz S, R.Neame: Vaccination in rheumatoid arthritis: Are your vaccinations up to date? Ann Rheum Dis 2013; 71:662. Gluck T. Vaccinate your immunocompromised patients. Rheumatology 2006:45:9–10. <h3>Disclosure of Interest</h3> R. Thakran: None declared, S. Baghel: None declared, R. Rawat: None declared, C. Messi: None declared, S. Kapoor Consultant for: Advisory board of Novartis,Pfizer, S. Garg Consultant for: Advisory board of Intas, A. Malaviya Consultant for: Advisory board of IPCA, Janssen, Pfizer, Roche, BMS,Dr. Reddy9s, Zydus
Effect of endotoxin and alum adjuvant vaccine on peanut allergy
Authors: Brandi T. Johnson-Weaver, Susan McRitchie, Kelly A. Mercier, Wimal Pathmasiri, Susan J. Sumner, Cliburn Chan, Dori Germolec, Michael Kulis, A. Wesley Burks, Herman F. Staats
Journal: Journal of Allergy and Clinical Immunology (2017)
GCT1021-01, a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817).
Authors: Ulrik Niels Lassen, Suresh S. Ramalingam, Juanita Suzanne Lopez, R Donald Harvey, Malaka Ameratunga, Jan de Hoon, Nedjad Losic, Steen Lisby, Ulf Forssmann, Ignace Vergote
Journal: Journal of Clinical Oncology (2017)

TPS2605 Background: HuMax-AXL-ADC is an antibody-drug conjugate (ADC) composed of an Axl-specific human monoclonal immunoglobulin G1 (IgG1κ) conjugated via a protease-cleavable valine-citrulline linker to the microtubule disrupting agent monomethyl auristatin E (MMAE). In vivo, HuMax-AXL-ADC demonstrated therapeutic anti-tumor efficacy in patient-derived xenograft models representing a variety of solid cancers, including pancreas, thyroid, lung, esophageal, cervical cancers and malignant melanoma. The non-clinical safety profile and pharmacokinetics (PK) of a once every 3 weeks (1Q3W) dosing schedule were established in cynomolgus monkeys. Methods: The primary objective of this trial is to determine the MTD and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors: ovarian, cervical, endometrial, thyroid cancer, NSCLC, and malignant melanoma. The trial consists of two parts, a phase I dose escalation part and a phase IIa expansion part. The dose escalation part explores two different dosing regimens: the first investigates doses from 0.3 up to 2.8 mg/kg to be administered 1Q3W. The second investigates doses in the range of 0.45 to 1.4 mg/kg to be administered weekly for 3 weeks followed by one treatment-free week (3Q4W dosing schedule). The second arm has a delayed start to inform a safe starting dose: when at least 8 patients have been evaluated for dose limiting toxicities, the 1.5 mg/kg cohort of the 1Q3W arm has been declared safe, and the predicted PK parameters of the starting dose in the 3Q4W arm are below pre-defined limits, the 3Q4W arm will be initiated. The 1Q3W arm follows a modified Bayesian Continuous Reassessment Method including escalation with overdose control in up to 41 patients on up to 7 main and 4 intermediate dose levels while the 3Q4W arm is run as a standard 3+3 trial design on up to 5-6 dose levels. In the phase IIa expansion part, further safety and biological activity data will be generated in selected indications using cohorts of 22 patients (11+11 patients in each cohort applying the Simon’s two-stage design). Clinical trial information: NCT 02988817.
AB0659 Association between -12518A/G gene polymorphism encoding monocyte chemoattractant protein 1 (MCP-1) and serum level of C-reactive protein in different clinical and serological phenotypes of systemic sclerosis in the russian cohort of patients
Authors: M Krylov, L Ananieva, O Koneva, M Starovoytova, O Desinova, O Ovsaynnikova, E Samarkina, A Novikov, E Aleksandrova
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Immune system activation with associated up-regulation in the production of extra-cellular matrix proteins by fibroblasts are known specific features in the pathogenesis of systemic scleroderma (SSc). Most recent data indicate that MCP-1 and MCP-3 chemokines from the family of monocyte chemoattractant proteins are also involved into SSc pathogenetic process. C-reactive protein (CRP) is known as the marker of acute-phase inflammation. The association between increased CRP levels and SSc clinical and serological parameters has been reported recently. <h3>Objectives</h3> To study the association between -2518 A/G gene polymorphism, encoding <i>MCP-1</i>, and CRP levels in different clinical SSc phenotypes in the Russian cohort of pts. <h3>Methods</h3> PCR-RFLP method was used to identify <i>MCP-1</i> genotype in 81 SSc pts aged 49,4±12,6 years, with mean SSc duration 11,1±9,0 years. CRP concentrations were measured with highly sensitive immunoturbidimertry method. <h3>Results</h3> CRP levels were correlated with <i>MCP-1</i> genotypes in pts with limited (lcSSc) and diffuse (dcSSc) phenotypes, with interstitial lung disease (ILD+), with SSc duration &gt;3 years, with increased CRP level (&gt;5 mg/L), with positive antibody titers to DNA topoisomerase I (ATA+) and antibody to centromeres (ACA+). A total cohort analysis showed that carriers of -2518AA genotype had higher mean CRP level versus G allele carriers (12,6±7,5 mg/L vs 4,9±4,8 mg/L, respectively, <i>p</i>=0,009), although similar trend was found in dcSSc phenotype (16,4±19,5 mg/L vs 6,1±4,4 mg/L, respectively, <i>p</i>=0,040). In pts with -2518AA genotype and SSc duration &gt;3 years mean CRP level was significantly higher than in G allele carriers (1,1±16,7 mg/L vs 4,5±4,4 mg/L, respectively, <i>p</i>=0,025). In (ILD+) and (ATA+) subgroup pts with -2518AA genotype demonstrated higher mean CRP levels as compared to G allele carriers (12,4±15,6 mg/L vs 5,5±5,1 mg/L, respectively, <i>p</i>=0,018; and 17,6±20,9 mg/L vs 5,5±5,5 mg/L, respectively, <i>p</i>=0,010). CRP levels (&gt;5 mg/L) were found in 31 (38%) pts and were significantly different between AA genotype carriers and G allele carriers (27,4±19,2 mg/L vs 10,4±3,8 mg/L, respectively, <i>p</i>=0,003). No associations between genetic variations in the <i>MCP-1</i> gene and CRP levels in lcSSc phenotype, SSc duration &lt;3 years, CRP levels &lt;5mg/L and (ACA+) pts were established. <h3>Conclusions</h3> Our data demonstrate that -2518A/G <i>MCP-1</i> gene polymorphism is closely associated with CRP levels, thus, it can be considered as a new marker, reflecting the severity of the disease and unfavorable SSc prognosis. <h3>Disclosure of Interest</h3> None declared
AB0829 Bone metabolism in liver transplant patients two-year study. influence of medical intervention prior to surgery and antiresorptive treatment
Authors: E Sánchez Labrador, E Grau Garcia, K Arévalo Ruales, JJ Fragio Gil, R Mazarío González, C Alcañiz Escandell, I Cánovas Olmos, I Chalmeta Verdejo, CM Feced Olmos, L Gonzalez Puig, J Ivorra Cortes, I Martínez Cordellat, C Nájera Herranz, R Negueroles Albuixech, JE Oller Rodriguez, FM Ortiz-Sanjuan, E Vicens Bernabeu, A Villota Bello, V Fornés Ferrer, D Marín Hervás, D Nájera Moya, A Moya Herraiz, JA Román Ivorra
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Osteoporosis is a frequent complication in patients with chronic liver diseases, mainly in advanced stages or with evidence of cholestasis. During the first few months after liver transplant (LT) it seems that there is an accelerated bone mass loss and greater fracture risk. <h3>Objectives</h3> To study the antiresorptive treatment effect in bone metabolism in patients undergoing LT and to evaluate whether medical intervention prior to LT decreases the risk of osteoporosis <h3>Methods</h3> We recruited patients from the LT Protocol of Osteoporotic Risk Assessment. The patients were evaluated 3–6 months before surgery, shortly after transplant (month 0) and 6–12–18–24 months after surgery. Data of bone metabolism biomarkers, densitometric values and antiresorptive treatment was collected. Biostatistical analysis with R (3.3.2.) was performed. <h3>Results</h3> We selected 163 LT patients of which 86 completed 24 months follow-up. From the total cohort, 77.8% were men and the mean age at transplantation 54.53±9.4 years old. 92.6% of patients were supplemented with vitamin D after surgery and 19.6% initiated antiresorptive treatment. We observed that 25-OHVitamin D, PTH, beta-CTX and P1NP levels were corrected through the follow-up. T-score during the first year of follow-up decreased slightly and at 24 months the tendency was towards increase. This pattern was stronger in lumbar spine (t-score -1.48±1.34 after surgery and -1.28±1.06 at 24 months). Statistical analysis showed that antiresorptive treatment significantly influence lumbar and hip densitometric values (P&lt;0.001 and P&lt;0.001 respectively) as well as P1NP levels (P=0.003 and P=0.012 respectively). Moreover, obesity (P=0.0004), as well as beta-CTX (P=0.029) and 25-OHVitamin D (P=0.024) standardization improved hip densitometric values. Finally, LT patients evaluated before surgery showed better lumbar densitometric values than those evaluated after the transplant (P=0.007). <h3>Conclusions</h3> We observed 25-OHVitamin D levels and bone metabolism biomarkers correction during the first two years after LT. Medical intervention prior to LT as well as antiresorptive treatment seem to play a decisive role in bone mineral density improvement. <h3>Disclosure of Interest</h3> None declared
Controlling Differentiation of Stem Cells for Developing Personalized Organ‐on‐Chip Platforms
Authors: Armin Geraili, Parya Jafari, Mohsen Sheikh Hassani, Behnaz Heidary Araghi, Mohammad Hossein Mohammadi, Amir Mohammad Ghafari, Sara Hasanpour Tamrin, Hassan Pezeshgi Modarres, Ahmad Rezaei Kolahchi, Samad Ahadian, Amir Sanati‐Nezhad
Journal: Advanced Healthcare Materials (2017)

Abstract Organ‐on‐chip (OOC) platforms have attracted attentions of pharmaceutical companies as powerful tools for screening of existing drugs and development of new drug candidates. OOCs have primarily used human cell lines or primary cells to develop biomimetic tissue models. However, the ability of human stem cells in unlimited self‐renewal and differentiation into multiple lineages has made them attractive for OOCs. The microfluidic technology has enabled precise control of stem cell differentiation using soluble factors, biophysical cues, and electromagnetic signals. This study discusses different tissue‐ and organ‐on‐chip platforms (i.e., skin, brain, blood–brain barrier, bone marrow, heart, liver, lung, tumor, and vascular), with an emphasis on the critical role of stem cells in the synthesis of complex tissues. This study further recaps the design, fabrication, high‐throughput performance, and improved functionality of stem‐cell‐based OOCs, technical challenges, obstacles against implementing their potential applications, and future perspectives related to different experimental platforms.
False-Positive Pancreatic Uptake Detected on 68Ga-PSMA PET/CT
Authors: Mehmet Onur Demirkol, Murat Can Kiremit, Omer Acar, Alan Alper Sag, Yersu Kapran
Journal: Clinical Nuclear Medicine (2017)

A 72-year-old man underwent Ga-PSMA PET/CT because of an elevated prostate-specific antigen level despite prior prostatectomy. Besides low-intensity prostatic PSMA reactivities, a faintly PSMA-positive lesion in the pancreatic corpus drew attention, which seemed suggestive of a primary pancreatic cancer on the subsequent MRI and therefore had to be excised. The final diagnosis was pT3 low-grade neuroendocrine tumor. PSMA-positive incidentalomas, detected on Ga-PSMA PET/CT, can reveal more clinically significant extraprostatic disorders.
THU0502 Efficacy and safety of canakinumab in patients with still's disease: a pooled analysis of sjia data by age groups
Authors: E Feist, P Quartier, B Fautrel, R Schneider, P Sfriso, P Efthimiou, L Cantarini, K Lheritier, K Leon, C Karyekar, A Speziale
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Still9s disease presents in paediatric and adult patients (pts) as a disease continuum with similar symptoms and pathophysiology.<sup>1,2</sup> <h3>Objectives</h3> To evaluate the efficacy and safety of canakinumab (CAN), a selective human anti-IL1 β monoclonal antibody, in SJIA pts from pooled data across 3 age groups (grps): children, adolescent and adults (the latter representing adult-onset Still9s disease [AOSD] population). <h3>Methods</h3> Data of CAN treated pts were pooled from 4 SJIA studies (NCT00426218, NCT00886769, NCT00889863, NCT00891046). CAN was administered at 4 mg/kg every 4 weeks (wk). Efficacy parameters (adapted ACR [aACR] paediatric responses, juvenile idiopathic arthritis [JIA] ACR responses, pts with inactive disease), CRP levels over 12 wk and safety were assessed by age grp. One study [NCT00426218] was excluded for efficacy outcomes. <h3>Results</h3> 216 children (2–&lt;12 years [y]), 56 adolescents (12–&lt;16 y) and 29 adults (≥16 y) were analysed for efficacy outcomes. The efficacy parameters across the 3 age grps were largely comparable (Table 1). The safety profile of CAN was similar across age grps (Table 2). One death was reported (adolescents grp). Clinical, laboratory and immunogenicity data showed no notable differences between the age grps. <h3>Conclusions</h3> Pooled analyses indicate similar efficacy of CAN across all the age grps of children, adolescents and adult SJIA pts. There were no meaningful differences in safety profiles across the different age grp. These analyses suggest similar efficacy of CAN in AOSD pts as observed in the SJIA pts. <h3>References</h3> Jamilloux. Immunol Res 2015;61:53–62. Nirmala. Pediatric Rheumatol 2015;13:50. <h3>Disclosure of Interest</h3> E. Feist Grant/research support from: Novartis, Consultant for: Novartis, P. Quartier Grant/research support from: Abbvie, Novartis, Pfizer, Chugai-Roche, Consultant for: Abbvie, Novartis, Pfizer, Sobi, Roche, Speakers bureau: Abbvie, Novartis, Sobi, Roche, B. Fautrel Grant/research support from: AbbVIe, MSD, Pfizer, Consultant for: AbbVie, Biogen, BMS, Celgène, Hospira, Janssen, Lilly, MSD, NORDIC Pharma, Pfizer, Roche, SOBI, UCB, R. Schneider Grant/research support from: Novartis, Consultant for: Novartis, P. Sfriso Consultant for: Novartis, P. Efthimiou: None declared, L. Cantarini Consultant for: Sobi, Novartis, Abbvie, K. Lheritier Employee of: Novartis, K. Leon Employee of: Novartis, C. Karyekar Employee of: Novartis, A. Speziale Employee of: Novartis
SP0129 Classification, diagnosis and differential diagnosis of axial spondyloarthritis by mri - including quiz cases
Authors: M Østergaard
Journal: Annals of the Rheumatic Diseases (2017)

Magnetic resonance imaging (MRI) is essential in the process of diagnosis of axial spondyloarthritis (axSpA) in clinical practice, as described in recent EULAR recommendations (1). However, several important differential diagnoses need to be considered. MRI is also key in the Assessment in SpondyloArthritis International Society (ASAS) classification criteria for axSpA (2), for which a consensus definition of a positive MRI was made in 2009 (3). The ASAS MRI working group has recently provided an updated definition of what is needed to fulfill the MRI-criterion in the ASAS criteria (4), based on a consensus excercise. This talk will describe the evidence behind the use of MRI for diagnosis of axSpA, describe the current ASAS consensus on how to use MRI for classification of axSpA, and examples of the most important differential diagnoses will be shown. The presentation will include patient cases for audience review. <h3>References</h3> Mandl P, Navarro-Compan V, Terslev L et al. EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis (Published online) 2015. Rudwaleit M, Landewe R, van der Heijde D et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; 68(6):770–776. Rudwaleit M, Jurik AG, Hermann KG, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 2009; 68(10):1520–1527. Lambert RG, Bakker PA, van der Heijde D et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Ann Rheum Dis (Published online) 2016. <h3>Disclosure of Interest</h3> None declared
NHS is warned to be on high alert for flu this winter
Authors: Jacqui Wise
Journal: BMJ (2017)

The head of NHS England has warned hospitals and GP surgeries to be prepared for a big increase in cases of flu this winter after a heavy season in the southern hemisphere.

Speaking at the Health and Care Innovation Expo in Manchester on Tuesday 12 September, NHS England’s chief executive, Simon Stevens, said that the NHS should be on high alert and should ensure that all measures are taken to prepare for the winter ahead. “For the next three, four, five months the top priority for every leader, every part of the NHS, is ensuring that the NHS goes into winter in a …
FRI0297 Role of serum interleukin-6 in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus
Authors: S Hirohata, Y Matsueda, T Yanagida, T Yoshio
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown of blood brain barrier (BBB) plays a crucial role in the development of diffuse psychiatric/neuropsychological manifestations (diffuse NPSLE), allowing influx of neuron-reactive autoantibodies from systemic circulation into the brain. However, the mechanism of BBB damages remains unclear. On the other hand, although CSF interleukin-6 (IL-6) has been shown to be elevated in NPSLE, there has been no report on serum IL-6 in NPSLE. <h3>Objectives</h3> The present study was designed in order to elucidate the roles of serum IL-6 in the pathogenesis, especially in development of BBB damages, In NPSLE. <h3>Methods</h3> Paired serum and cerebrospinal fluid (CSF) samples were obtained from 101 SLE patients when they presented active neuropsychiatric manifestations (69 patients with diffuse psychiatric/neuropsychological syndromes [diffuse NPSLE] and 32 patients with neurologic syndromes or peripheral nervous system involvement [focal NPSLE]) and from 22 non-SLE control patients with non-inflammatory neurological diseases. The levels of albumin and IL-6 in CSF and sera were measured by ELISA. <h3>Results</h3> Serum IL-6 as well as CSF IL-6 was significantly elevated in acute confusional state (ACS) compared with non-ACS diffuse NPSLE (anxiety disorder, cognitive dysfunction, mood disorder and psychosis) or focal NPSLE (figure). Q albumin (CSF/serum albumin quotient) was also significantly higher in ACS than in the other 2 groups of NPSLE. Of note, serum IL-6 (r=0.2801, p=0.0207), but not CSF IL-6 (r=0.1602, p=0.1918), was significantly correlated with Q albumin in patients with diffuse NPSLE, including ACS and non-ACS, although serum IL-6 was significantly correlated with CSF IL-6 in this population (r=0.3205, p=0.082). <h3>Conclusions</h3> These results indicate that serum IL-6 as well as IL-6 is involved in the pathogenesis of NPSLE. The data also confirm that the severity of BBB damages plays a crucial role in the development of ACS, the severest form of diffuse NPSLE. Finally, it is suggested that serum IL-6 might play a most important role in BBB breakdown in NPSLE, whereas CSF IL-6 might be involved in subsequent central nervous system inflammation. <h3>Disclosure of Interest</h3> None declared